Noopept (N-phenylacetyl-L-prolylglycine ethyl ester)

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic dipeptide-derived nootropic originally developed in Russia that acts primarily as an ampakine-like compound, modulating AMPA and NMDA glutamate receptors to enhance synaptic plasticity. Its key bioactive mechanism involves upregulating NGF and BDNF expression in hippocampal and cortical tissue, with most supporting evidence coming from rodent and in vitro studies rather than large human clinical trials.

Origin & History

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic nootropic dipeptide compound developed at the State Zakusov Institute of Pharmacology in Russia, designed to mimic the effects of piracetam through peptide design. It is produced synthetically through a multi-step chemical process involving phenylacetyl chloride reaction with intermediates, followed by dehydration-condensation of N-phenylacetyl-L-proline and glycine ethyl ester using DCC/DMAP catalysts.

Historical & Cultural Context

Noopept has no traditional or historical use in medicine systems as it is a modern synthetic compound developed in the late 20th century at the State Zakusov Institute of Pharmacology in Russia.

Health Benefits

• May increase acetylcholine signaling in the brain (mechanism identified in preclinical research only)
• Could boost expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) (based on molecular studies, no human trials)
• Potentially modulates inflammation via BDNF pathways (shown in rat model study PMC7895721)
• May influence neuroprotective pathways through HIF-1 modulation (molecular docking studies only)
• Designed for nootropic effects similar to piracetam (theoretical basis, no human clinical evidence provided)

How It Works

Noopept modulates AMPA-type glutamate receptors and potentiates NMDA receptor activity, enhancing long-term potentiation (LTP) in hippocampal neurons, which underlies synaptic strengthening and memory consolidation. It also upregulates the transcription of BDNF and NGF in the hippocampus and prefrontal cortex, neurotrophins critical for neuronal survival, synaptic growth, and cholinergic neurotransmission. Additionally, Noopept increases alpha/beta1 oscillatory brain activity and may inhibit acetylcholinesterase activity, indirectly elevating acetylcholine availability at muscarinic and nicotinic receptors.

Scientific Research

The available research on Noopept is limited to preclinical studies, with no human clinical trials, RCTs, or meta-analyses identified in the research dossier. One notable study (PMC7895721) examined Noopept's modulation of inflammation via BDNF in a rat model, showing effects on spinal microglia, but this remains preclinical evidence only.

Clinical Summary

Preclinical rodent studies have demonstrated Noopept's ability to reverse scopolamine-induced amnesia and improve spatial memory in maze tasks at doses of 0.1–10 mg/kg. A small Russian open-label trial involving approximately 53 patients with mild cognitive impairment reported subjective improvements in memory and attention over 56 days at 10–30 mg/day oral doses, but the study lacked a placebo control and blinding. No large-scale, double-blind, randomized controlled trials in healthy human populations have been published as of current literature, making efficacy claims in humans preliminary at best. The overall evidence base is substantially weaker than for more established nootropics, and independent replication outside Russian research institutions remains sparse.

Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable", "carbohydrates": "Not applicable", "fats": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"N-phenylacetyl-L-prolylglycine ethyl ester": "Exact concentration not specified; typically administered in doses ranging from 10-30 mg per day in research settings"}, "bioavailability_notes": "Noopept is a synthetic compound and does not have a traditional nutritional profile. Its bioavailability is influenced by factors such as administration route and individual metabolic differences. It is rapidly absorbed and crosses the blood-brain barrier, but specific absorption rates and bioavailability percentages are not well-documented in human studies."}

Preparation & Dosage

No clinically studied dosage ranges are available from human trials. The compound is supplied as a synthetic powder with no standardization information provided in the research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Piracetam, Alpha-GPC, Lion's Mane, Phosphatidylserine, Rhodiola

Safety & Interactions

Noopept is generally reported as well-tolerated at doses of 10–30 mg/day in short-term use, with commonly noted side effects including headache, irritability, sleep disturbances, and elevated blood pressure in sensitive individuals. Due to its modulation of glutamatergic pathways, combining Noopept with other glutamate-enhancing agents or stimulants such as racetams, caffeine, or amphetamine-class drugs may increase risk of overstimulation or excitotoxicity. Noopept may potentiate psychostimulant effects and should be used cautiously alongside SSRIs, MAOIs, or other CNS-active medications due to theoretical serotonergic and dopaminergic interactions. Safety data for pregnant or breastfeeding individuals is entirely absent, making use contraindicated in these populations; individuals with hypertension, anxiety disorders, or a history of psychosis should also avoid use without medical supervision.